News 14.10.2023 Schlieren (Zurich), October 9, 2023 - LimmaTech Biologics AG today announced the closing of a USD 37 million (CHF 33 million) Series A financing round co-led by Adjuvant Capital, AXA IM Alts, and the Novo Holdings REPAIR Impact Fund. The proceeds will enable LimmaTech to advance its proprietary technology platform...
News 18.09.2023 Switzerland, 18 September 2023 – CUTISS AG, a Swiss clinical-stage life sciences company focused on skin regenerative medicine and tissue engineering, has announced the launch of its Series C for the next stage of the company’s development. CUTISS seeks to raise the Series C with the participation of existing and new investors to...
News 13.09.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Sept. 13, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announces new data from its Radio-DARPin Therapy (RDT) platform pertaining to potential efficacy...
News 11.09.2023 Zurich, Switzerland – September 7, 2023 InSphero today announced that the company is making their 3D in vitro products available to researchers in the European Union market more easily by signing a distribution agreement with Darwin Microfluidics, an innovative startup dedicated to bringing advanced microfluidic solutions to researchers worldwide. InSphero, a global pioneer in 3D cell...
News 25.08.2023 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Aug. 24, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR: Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biopharmaceutical company developing a new class of custom-built protein drugs known as DARPin therapeutics ("Molecular Partners" or the "Company"), today announced corporate highlights and unaudited...